Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
Petya Apostolova*, Stefanie Kreutmair, Cristina Toffalori, Marco Punta, Susanne Unger, Ann Cathrin Burk, Claudia Wehr, Kristina Maas-Bauer, Wolfgang Melchinger, Eileen Haring, Rouven Hoefflin, Khalid Shoumariyeh, Valerie Hupfer, Eliza Maria Lauer, Sandra Duquesne, Theresa Lowinus, Nicolás Gonzalo Núñez, Chiara Alberti, Sara da Costa Pereira, Carla Helena MertenLaura Power, Matthias Weiss, Caroline Böke, Dietmar Pfeifer, Reinhard Marks, Hartmut Bertz, Ralph Wäsch, Gabriele Ihorst, Bernhard Gentner, Justus Duyster, Melanie Boerries, Geoffroy Andrieux, Juergen Finke, Burkhard Becher, Luca Vago, Robert Zeiser*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response'. Together they form a unique fingerprint.